Loading…
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that has caused the recent coronavirus disease (COVID-19) global pandemic. The current approved COVID-19 vaccines have shown considerable efficiency against hospitalization and death. However, the continuation of the p...
Saved in:
Published in: | Progress in biophysics and molecular biology 2023-03, Vol.178, p.32-49 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3 |
---|---|
cites | cdi_FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3 |
container_end_page | 49 |
container_issue | |
container_start_page | 32 |
container_title | Progress in biophysics and molecular biology |
container_volume | 178 |
creator | Bayani, Fatemeh Hashkavaei, Negin Safaei Arjmand, Sareh Rezaei, Shokouh Uskoković, Vuk Alijanianzadeh, Mahdi Uversky, Vladimir N. Ranaei Siadat, Seyed Omid Mozaffari-Jovin, Sina Sefidbakht, Yahya |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that has caused the recent coronavirus disease (COVID-19) global pandemic. The current approved COVID-19 vaccines have shown considerable efficiency against hospitalization and death. However, the continuation of the pandemic for more than two years and the likelihood of new strain emergence despite the global rollout of vaccination highlight the immediate need for the development and improvement of vaccines. mRNA, viral vector, and inactivated virus vaccine platforms were the first members of the worldwide approved vaccine list. Subunit vaccines. which are vaccines based on synthetic peptides or recombinant proteins, have been used in lower numbers and limited countries. The unavoidable advantages of this platform, including safety and precise immune targeting, make it a promising vaccine with wider global use in the near future. This review article summarizes the current knowledge on different vaccine platforms, focusing on the subunit vaccines and their clinical trial advancements against COVID-19.
[Display omitted] |
doi_str_mv | 10.1016/j.pbiomolbio.2023.02.004 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9938630</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0079610723000160</els_id><sourcerecordid>2778978504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS0EokvLV0A-ckk6_pM4viCVLZRKlXqpOFWyHGfCepXEi-1sxbcn7baFnnqZOcx7b0bzI4QyKBmw-nRb7lofxjAsteTARQm8BJBvyIo1ShRMCf6WrACULmoG6oh8SGkLAJyp-j05EnUDTCq2IrdnEw17jHuPdzT0NG-Q7q1zfkK6G2zuQxwTzYG6MLY20_X1z8vzgml65_OGWtoHNycapgdjmtt58vkpIJ2Qd70dEn587Mfk5vu3m_WP4ur64nJ9dlU4qXQuGoVCWuGqrqt17RgHZ1F1ki3nikZrJStbWVZXTNYaW6etaKRTsu84itaJY_LlELub2xE7h1OOdjC76Ecb_5hgvXk5mfzG_Ap7o7VoagFLwOfHgBh-z5iyGX1yOAx2wjAnw5VqtGoqkIu0OUhdDClF7J_XMDD3bMzW_GNj7tkY4AYerJ_-P_PZ-ARjEXw9CHD51QIkmuQ8Tg47H9Fl0wX_-pa_xcGl9w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2778978504</pqid></control><display><type>article</type><title>An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines</title><source>Elsevier</source><creator>Bayani, Fatemeh ; Hashkavaei, Negin Safaei ; Arjmand, Sareh ; Rezaei, Shokouh ; Uskoković, Vuk ; Alijanianzadeh, Mahdi ; Uversky, Vladimir N. ; Ranaei Siadat, Seyed Omid ; Mozaffari-Jovin, Sina ; Sefidbakht, Yahya</creator><creatorcontrib>Bayani, Fatemeh ; Hashkavaei, Negin Safaei ; Arjmand, Sareh ; Rezaei, Shokouh ; Uskoković, Vuk ; Alijanianzadeh, Mahdi ; Uversky, Vladimir N. ; Ranaei Siadat, Seyed Omid ; Mozaffari-Jovin, Sina ; Sefidbakht, Yahya</creatorcontrib><description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that has caused the recent coronavirus disease (COVID-19) global pandemic. The current approved COVID-19 vaccines have shown considerable efficiency against hospitalization and death. However, the continuation of the pandemic for more than two years and the likelihood of new strain emergence despite the global rollout of vaccination highlight the immediate need for the development and improvement of vaccines. mRNA, viral vector, and inactivated virus vaccine platforms were the first members of the worldwide approved vaccine list. Subunit vaccines. which are vaccines based on synthetic peptides or recombinant proteins, have been used in lower numbers and limited countries. The unavoidable advantages of this platform, including safety and precise immune targeting, make it a promising vaccine with wider global use in the near future. This review article summarizes the current knowledge on different vaccine platforms, focusing on the subunit vaccines and their clinical trial advancements against COVID-19.
[Display omitted]</description><identifier>ISSN: 0079-6107</identifier><identifier>ISSN: 1873-1732</identifier><identifier>EISSN: 1873-1732</identifier><identifier>DOI: 10.1016/j.pbiomolbio.2023.02.004</identifier><identifier>PMID: 36801471</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>COVID-19 ; COVID-19 Vaccines ; Humans ; Knowledge ; Omicron ; SARS-CoV-2 ; Subunit vaccine ; Vaccine platforms ; Vaccines, Subunit</subject><ispartof>Progress in biophysics and molecular biology, 2023-03, Vol.178, p.32-49</ispartof><rights>2023 Elsevier Ltd</rights><rights>Copyright © 2023 Elsevier Ltd. All rights reserved.</rights><rights>2023 Elsevier Ltd. All rights reserved. 2023 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3</citedby><cites>FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27898,27899</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36801471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bayani, Fatemeh</creatorcontrib><creatorcontrib>Hashkavaei, Negin Safaei</creatorcontrib><creatorcontrib>Arjmand, Sareh</creatorcontrib><creatorcontrib>Rezaei, Shokouh</creatorcontrib><creatorcontrib>Uskoković, Vuk</creatorcontrib><creatorcontrib>Alijanianzadeh, Mahdi</creatorcontrib><creatorcontrib>Uversky, Vladimir N.</creatorcontrib><creatorcontrib>Ranaei Siadat, Seyed Omid</creatorcontrib><creatorcontrib>Mozaffari-Jovin, Sina</creatorcontrib><creatorcontrib>Sefidbakht, Yahya</creatorcontrib><title>An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines</title><title>Progress in biophysics and molecular biology</title><addtitle>Prog Biophys Mol Biol</addtitle><description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that has caused the recent coronavirus disease (COVID-19) global pandemic. The current approved COVID-19 vaccines have shown considerable efficiency against hospitalization and death. However, the continuation of the pandemic for more than two years and the likelihood of new strain emergence despite the global rollout of vaccination highlight the immediate need for the development and improvement of vaccines. mRNA, viral vector, and inactivated virus vaccine platforms were the first members of the worldwide approved vaccine list. Subunit vaccines. which are vaccines based on synthetic peptides or recombinant proteins, have been used in lower numbers and limited countries. The unavoidable advantages of this platform, including safety and precise immune targeting, make it a promising vaccine with wider global use in the near future. This review article summarizes the current knowledge on different vaccine platforms, focusing on the subunit vaccines and their clinical trial advancements against COVID-19.
[Display omitted]</description><subject>COVID-19</subject><subject>COVID-19 Vaccines</subject><subject>Humans</subject><subject>Knowledge</subject><subject>Omicron</subject><subject>SARS-CoV-2</subject><subject>Subunit vaccine</subject><subject>Vaccine platforms</subject><subject>Vaccines, Subunit</subject><issn>0079-6107</issn><issn>1873-1732</issn><issn>1873-1732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkU9v1DAQxS0EokvLV0A-ckk6_pM4viCVLZRKlXqpOFWyHGfCepXEi-1sxbcn7baFnnqZOcx7b0bzI4QyKBmw-nRb7lofxjAsteTARQm8BJBvyIo1ShRMCf6WrACULmoG6oh8SGkLAJyp-j05EnUDTCq2IrdnEw17jHuPdzT0NG-Q7q1zfkK6G2zuQxwTzYG6MLY20_X1z8vzgml65_OGWtoHNycapgdjmtt58vkpIJ2Qd70dEn587Mfk5vu3m_WP4ur64nJ9dlU4qXQuGoVCWuGqrqt17RgHZ1F1ki3nikZrJStbWVZXTNYaW6etaKRTsu84itaJY_LlELub2xE7h1OOdjC76Ecb_5hgvXk5mfzG_Ap7o7VoagFLwOfHgBh-z5iyGX1yOAx2wjAnw5VqtGoqkIu0OUhdDClF7J_XMDD3bMzW_GNj7tkY4AYerJ_-P_PZ-ARjEXw9CHD51QIkmuQ8Tg47H9Fl0wX_-pa_xcGl9w</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>Bayani, Fatemeh</creator><creator>Hashkavaei, Negin Safaei</creator><creator>Arjmand, Sareh</creator><creator>Rezaei, Shokouh</creator><creator>Uskoković, Vuk</creator><creator>Alijanianzadeh, Mahdi</creator><creator>Uversky, Vladimir N.</creator><creator>Ranaei Siadat, Seyed Omid</creator><creator>Mozaffari-Jovin, Sina</creator><creator>Sefidbakht, Yahya</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230301</creationdate><title>An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines</title><author>Bayani, Fatemeh ; Hashkavaei, Negin Safaei ; Arjmand, Sareh ; Rezaei, Shokouh ; Uskoković, Vuk ; Alijanianzadeh, Mahdi ; Uversky, Vladimir N. ; Ranaei Siadat, Seyed Omid ; Mozaffari-Jovin, Sina ; Sefidbakht, Yahya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>COVID-19</topic><topic>COVID-19 Vaccines</topic><topic>Humans</topic><topic>Knowledge</topic><topic>Omicron</topic><topic>SARS-CoV-2</topic><topic>Subunit vaccine</topic><topic>Vaccine platforms</topic><topic>Vaccines, Subunit</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bayani, Fatemeh</creatorcontrib><creatorcontrib>Hashkavaei, Negin Safaei</creatorcontrib><creatorcontrib>Arjmand, Sareh</creatorcontrib><creatorcontrib>Rezaei, Shokouh</creatorcontrib><creatorcontrib>Uskoković, Vuk</creatorcontrib><creatorcontrib>Alijanianzadeh, Mahdi</creatorcontrib><creatorcontrib>Uversky, Vladimir N.</creatorcontrib><creatorcontrib>Ranaei Siadat, Seyed Omid</creatorcontrib><creatorcontrib>Mozaffari-Jovin, Sina</creatorcontrib><creatorcontrib>Sefidbakht, Yahya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Progress in biophysics and molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bayani, Fatemeh</au><au>Hashkavaei, Negin Safaei</au><au>Arjmand, Sareh</au><au>Rezaei, Shokouh</au><au>Uskoković, Vuk</au><au>Alijanianzadeh, Mahdi</au><au>Uversky, Vladimir N.</au><au>Ranaei Siadat, Seyed Omid</au><au>Mozaffari-Jovin, Sina</au><au>Sefidbakht, Yahya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines</atitle><jtitle>Progress in biophysics and molecular biology</jtitle><addtitle>Prog Biophys Mol Biol</addtitle><date>2023-03-01</date><risdate>2023</risdate><volume>178</volume><spage>32</spage><epage>49</epage><pages>32-49</pages><issn>0079-6107</issn><issn>1873-1732</issn><eissn>1873-1732</eissn><abstract>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that has caused the recent coronavirus disease (COVID-19) global pandemic. The current approved COVID-19 vaccines have shown considerable efficiency against hospitalization and death. However, the continuation of the pandemic for more than two years and the likelihood of new strain emergence despite the global rollout of vaccination highlight the immediate need for the development and improvement of vaccines. mRNA, viral vector, and inactivated virus vaccine platforms were the first members of the worldwide approved vaccine list. Subunit vaccines. which are vaccines based on synthetic peptides or recombinant proteins, have been used in lower numbers and limited countries. The unavoidable advantages of this platform, including safety and precise immune targeting, make it a promising vaccine with wider global use in the near future. This review article summarizes the current knowledge on different vaccine platforms, focusing on the subunit vaccines and their clinical trial advancements against COVID-19.
[Display omitted]</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36801471</pmid><doi>10.1016/j.pbiomolbio.2023.02.004</doi><tpages>18</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0079-6107 |
ispartof | Progress in biophysics and molecular biology, 2023-03, Vol.178, p.32-49 |
issn | 0079-6107 1873-1732 1873-1732 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9938630 |
source | Elsevier |
subjects | COVID-19 COVID-19 Vaccines Humans Knowledge Omicron SARS-CoV-2 Subunit vaccine Vaccine platforms Vaccines, Subunit |
title | An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-26T10%3A09%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20overview%20of%20the%20vaccine%20platforms%20to%20combat%20COVID-19%20with%20a%20focus%20on%20the%20subunit%20vaccines&rft.jtitle=Progress%20in%20biophysics%20and%20molecular%20biology&rft.au=Bayani,%20Fatemeh&rft.date=2023-03-01&rft.volume=178&rft.spage=32&rft.epage=49&rft.pages=32-49&rft.issn=0079-6107&rft.eissn=1873-1732&rft_id=info:doi/10.1016/j.pbiomolbio.2023.02.004&rft_dat=%3Cproquest_pubme%3E2778978504%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2778978504&rft_id=info:pmid/36801471&rfr_iscdi=true |